When was Naurex founded?

Naurex was founded in 2008 and raised its 1st funding round 3 years after it was founded.

Where is Naurex located?

Naurex is headquartered in Evanston, United States.

Is Naurex a funded company?

Naurex is a funded company, having raised a total of $162M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 04, 2011.

When was the latest funding round of Naurex?

Naurex's latest funding was a $***** Series C round on Dec 02, 2015, with participation from 12 investors. Its primary sector is Neurology. In United States, the Neurology sector has seen $3.67B in funding in 2026 to date.

Where does Naurex rank among its competitors?

Naurex ranks 4th amongst 7 active competitors, of which 3 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Draigtherapeutics, which secured $65M in Jul, 2026.

Who are the top competitors of Naurex?

Naurex's top competitors include Tonix Pharma, Draigtherapeutics and Evecxia Therapeutics. Among them, Draigtherapeutics secured the most recent funding round in July, 2026.

Naurex - 2026 Company Profile, Team, Funding & Competitors

Q: Is Naurex an acquired company?

Naurex got acquired by Allergan on Jul 26, 2015.

Naurex is an acquired company based in Evanston (United States), founded in 2008 by Joseph Moskal. It operates as a Clinical-stage company developing novel therapies for depression and other CNS disorders.. Naurex has raised $162M in funding from investors like Adams Street Partners, Takeda Ventures and Northwestern University. The company has 7 active competitors, including 3 funded and 2 that have exited. Its top competitors include companies like Tonix Pharma, Draigtherapeutics and Evecxia Therapeutics.

Company Details

Naurex is a clinical-stage company developing novel therapies for depression and other CNS disorders. The company lead product candidate, Rapastinel, is in late-stage clinical development as an adjunctive therapy for patients with major depressive disorder. The company's second-generation compound, NRX-1074, is an orally active agent in Phase 2 clinical development as a monotherapy for the treatment of major depressive disorder.

Key Metrics

Founded Year

2008

Location

Evanston, United States

Stage

Acquired

Total Funding

$162M in 5 rounds

Latest Funding Round

Series C, Dec 02, 2015, $*****

Investors

Adams Street Partners & 14 more

Ranked

4^th among 7 active competitors

Similar Companies

Tonix Pharma & 5 more

Exit Details

Acquired by Allergan (Jul 26, 2015)

View Naurex's full profile

Naurex is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Naurex Inc. CIN: 260775044 , United States, Active	Dec 31, 2007	-	-	-

Naurex got acquired by Allergan on Jul 26, 2015 at an acquisition amount of $*****.

Click here to take a look at Naurex's acquisition in detail

Naurex has raised a total funding of $162M over 5 rounds. Its first funding round was on Feb 04, 2011. Its latest funding round was a Series C round on Dec 02, 2015 for $*****. 12 investors participated in its latest round. Naurex has 15 institutional investors.

Here is the list of recent funding rounds of Naurex:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 02, 2015	3689895	Series C	9911964	6941800	1145703	3007976
May 06, 2014	9908963	Series B	4881864	3649160	8009716	Adams Street Partners & 1 more
Dec 17, 2012	1632424	Series B	2915452	9875267	Baxter Ventures	Savitr Capital & 6 more

Access funding benchmarks and valuations. Sign up today!

View details of Naurex's funding rounds and investors

The founders of Naurex is Joseph Moskal.

Here are the details of Naurex's key team members:

Joseph Moskal: Founder of Naurex.

View details of Naurex's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Naurex include Tonix Pharma, Draigtherapeutics and Evecxia Therapeutics. Here is the list of Top 10 competitors of Naurex, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Tonix Pharma 2007, New York City (United States), Public	Developer of next-generation medicines for CNS and immunological disorders	$4.45M	Westwicke, Technology Partners & 2 others	66/100
2nd	Draigtherapeutics 2021, Cardiff (United Kingdom), Series B	Developer of targeted neuromodulators for neuropsychiatric disorders treatment	$205M	Access Industries, Deep Track Capital & 9 others	60/100
3rd	Evecxia Therapeutics 2013, Durham (United States), Series A	Developing 5-HTP drugs to amplify serotonin for mental illness treatment	$14.9M	Collage Venture Partners, Transhuman Capital ... & 2 others	52/100
4th	Naurex 2008, Evanston (United States), Acquired	Clinical-stage company developing novel therapies for depression and other CNS disorders.	$162M	Adams Street Partners, Cowen & 13 others	45/100
5th	EmbarkNeuro 2021, Oakland (United States), Unfunded	Developer of therapeutics for the treatment of mental health disorders	-	-	28/100
6th	Mind Pharmaceuticals 2024, New Haven (United States), Seed	Developer of short-acting, rapid-onset DMT-based treatments for treatment-resistant depression	$50K	-	24/100
7th	Obi 2002, Taipei (Taiwan), Unfunded	Provider of at-home cortisol saliva tests for stress management	-	-	16/100